OncoNano Medicine, Inc. has entered into a strategic research collaboration with Gilead Sciences to apply its proprietary ON-BOARD™ nanoparticle encapsulation technology to one of Gilead’s early-stage drug candidates. Under the agreement, teams from both companies will jointly evaluate the stability profile, cellular selectivity, and in vitro efficacy of Gilead’s molecule when loaded into OncoNano’s lipid-based carriers. The program will run through multiple preclinical milestones over the next 12 months, with each stage linked to success-based funding tranches. By harnessing ON-BOARD’s targeted delivery capabilities, Gilead aims to improve the bioavailability of its candidate compound and potentially reduce dosing requirements. The collaboration underscores Gilead’s commitment to enhancing its drug development platform through external partnerships and could pave the way for broader application of nanoparticle delivery across its pipeline.